These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30003535)

  • 1. Egos has a reduced capacity to predicts GBS prognosis in Northeast Brazil.
    Dourado Júnior MET; Fernandes UT; Ramos ES; Vital ALF; Urbano JCC; Queiroz JW; Jeronimo SMB
    Acta Neurol Scand; 2018 Nov; 138(5):459-462. PubMed ID: 30003535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of Guillain-Barré syndrome prognostic models in Malaysian patients.
    Tan CY; Razali SNO; Goh KJ; Shahrizaila N
    J Peripher Nerv Syst; 2019 Jun; 24(2):168-173. PubMed ID: 31001904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability and validity of prognostic indicators for Guillain-Barré syndrome in children.
    Qinrong H; Yuxia C; Ling L; Huayu L; Lei X; Xiaoli L; Nong X
    Dev Med Child Neurol; 2023 Apr; 65(4):563-570. PubMed ID: 36175376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study.
    Forsberg A; Press R; Holmqvist LW
    J Neurol Sci; 2012 Jun; 317(1-2):74-9. PubMed ID: 22425539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in Guillain-Barré syndrome].
    Kaida K
    Rinsho Shinkeigaku; 2013; 53(11):1315-8. PubMed ID: 24291972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of Guillain-Barré syndrome in a tropical country: a Brazilian experience.
    Dourado ME; Félix RH; da Silva WK; Queiroz JW; Jeronimo SM
    Acta Neurol Scand; 2012 Jan; 125(1):47-53. PubMed ID: 21428966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild Guillain-Barré syndrome.
    Green DM; Ropper AH
    Arch Neurol; 2001 Jul; 58(7):1098-101. PubMed ID: 11448299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prognosis and prognostic factor of Guillain-Barré Syndrome].
    Yamagishi Y; Kusunoki S
    Rinsho Shinkeigaku; 2020 Apr; 60(4):247-252. PubMed ID: 32238748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome.
    Roodbol J; Korinthenberg R; Venema E; de Wit MY; Lingsma HF; Catsman-Berrevoets CE; Jacobs BC; ;
    Eur J Paediatr Neurol; 2023 May; 44():18-24. PubMed ID: 36931152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes.
    Chakraborty T; Kramer CL; Wijdicks EFM; Rabinstein AA
    Neurocrit Care; 2020 Feb; 32(1):113-120. PubMed ID: 31297663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical prognostic scoring system for Guillain-Barré syndrome.
    van Koningsveld R; Steyerberg EW; Hughes RA; Swan AV; van Doorn PA; Jacobs BC
    Lancet Neurol; 2007 Jul; 6(7):589-94. PubMed ID: 17537676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for Neuroprognostication in Adults with Guillain-Barré Syndrome.
    Busl KM; Fried H; Muehlschlegel S; Wartenberg KE; Rajajee V; Alexander SA; Creutzfeldt CJ; Fontaine GV; Hocker SE; Hwang DY; Kim KS; Madzar D; Mahanes D; Mainali S; Meixensberger J; Sakowitz OW; Varelas PN; Westermaier T; Weimar C
    Neurocrit Care; 2023 Jun; 38(3):564-583. PubMed ID: 36964442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
    Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
    Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation.
    van den Berg B; Storm EF; Garssen MJP; Blomkwist-Markens PH; Jacobs BC
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):949-954. PubMed ID: 29627773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
    Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
    Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barré Syndrome in a Brazilian population.
    Dourado ME; Ferreira LC; Freire-Neto FP; Jeronimo SM
    J Neuroimmunol; 2016 Sep; 298():160-4. PubMed ID: 27609290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcome of Guillain-Barré syndrome in Iceland: A population-based study.
    Hafsteinsdóttir B; Ólafsson E; Jakobsson F
    Acta Neurol Scand; 2018 Nov; 138(5):454-458. PubMed ID: 30019469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.